A Very Early Rehabilitation Trial (AVERT)

April 13, 2015 updated by: Neuroscience Trials Australia

A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.

Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days.

Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.

Study Overview

Status

Completed

Conditions

Detailed Description

People who suffer a stroke are often left with disabilities such as weakness, or problems with speech, thinking, or control or bodily functions. Severe strokes often result in death. The results of a recent European study indicated that patients who commence mobility training very early after a stroke (Day 1) recover the ability to walk more quickly and return home sooner and in greater numbers than those who start training one week or later after stroke. Recently a phase II (pilot) AVERT study was conducted in which the investigators tested the safety and feasibility of very early mobilisation (European model) Stroke patients in this study randomly received either standard care or very early mobilisation (VEM). The study showed that there was no harm to patients in the VEM group compared to those who had standard care and that delivering VEM was feasible. Consequently, a grant to conduct the larger phase III study, to test the effectiveness of the intervention was obtained.

In this next phase III trial, the investigators aim to look at 2104 patients across stroke care units in city and regional hospitals. Each hospital will be asked to include between 30 and 60 patients per year to the study. All stroke patients admitted to the hospital Stroke Unit or ward at the hospital will be invited to participate. Medical clearance will be obtained for all potential participants. Those unconscious or too ill, together with those already participating in acute drug trials will be excluded. Patients who are able will provide their own consent to participate. Those who are not able to consent for themselves will have a third party (usually a relative) acknowledge their participation in the study. As this is a blinded controlled trial, keeping the assessor and patients unaware of their treatment group is important. The investigators will inform patients that they will have a 50% chance of receiving one of two rehabilitation types during their hospitalization if they decide to participate. Patients in the VEM group will commence treatment within 24 hours of admission to hospital. VEM will be provided by a trained AVERT physiotherapist, and AVERT study nurse and aims to improve functional mobility. The mobilization activities will depend on the patient's functional ability and tolerance to exercise. Patients will be closely monitored prior to mobilization and will only be mobilised if they meet requirements for blood pressure and other vital signs. The number of sessions and the time spent for each patient will vary, however specific targets are to be met according to the intervention protocol. The content and timing of all treatment received by participants in either group will be recorded. The treatment period for this study is from the time of the patients consent, until day 14 or discharge from the stroke unit or ward. (Whichever is earlier). All participants will be assessed at admission to the study, 3 months, and 12 months after their stroke. Information collected by the AVERT physiotherapists and nurses and the assessor will be recorded on individual case record forms and on a secure web based data base. Therapists also add some information to a palm pilot, and then download it onto the secure website. All information collected from patients will be treated as confidential in line with international guidelines and local law.

The primary outcome measure for the study is the number of patients dead and disabled at 3 months after stroke. Other secondary outcome measures include the safety of patients, quality of life, and cost effectiveness. An independent Data Monitoring committee will monitor the safety, conduct and efficacy of the trial. In addition, an independent outcomes committee will be reviewing all events that are reported as serious.

Study Type

Interventional

Enrollment (Anticipated)

2014

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Victoria
      • Melbourne, Victoria, Australia, 3084
        • Florey Institute for Neuroscience and Mental health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed consent
  • Clinical diagnosis of first or recurrent stroke, hemorrhage or infarct.
  • Recruited within 24 hours of onset of stroke symptoms
  • Admission in a stroke care unit
  • Consciousness: At a minimum patient must at least react to verbal commands.

Exclusion Criteria:

  • pre stroke mRS of 3,4 or 5
  • Deterioration in patients condition resulting in direct admission to ICU, decision to palliate or surgery.
  • Concurrent diagnosis of rapidly deteriorating disease
  • Unstable coronary or other medical condition that is judged by the investigator to impose a hazard to the patient by involvement
  • Patients unable to be mobilized within 24 hours of onset. (eg bed rest policy post tPA, lower limb fracture)
  • Other interventional trials
  • Systolic BP less than 110 or greater than 220mmHg
  • Oxygen saturation of less than 92 % with supplementation
  • Resting heart rate of less than 40 or greater than 110 beats per minute
  • Temperature of greater than 38.5 degrees C

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Standard Care
Standard stroke unit rehabilitation care
Experimental: Standard Care + VEM
Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
modified Rankin Score
Time Frame: 3 months
Favorable outcome (0-2) modified Rankin Score
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety. Death rate and severity of important medical events
Time Frame: up until 3 months
Important medical events (stroke progression, recurrent stroke, falls, angina, myocardial infarction, deep vein thrombosis, pulmonary emboli, pressure sores, chest infections, urinary tract infections, depression) at 3 months.
up until 3 months
Time to unassisted walking over 50 meters and the proportion achieving unassisted walking
Time Frame: 3 Months
Achieves walking independently or with supervision over 50 meters
3 Months
modified Rankin Score
Time Frame: 3 months
Assumption free ordinal approach
3 months
Health related Quality of life
Time Frame: 12 months
AQoL
12 months
Cost effectiveness and cost utility
Time Frame: 12 months
comprehensive questionaire
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Julie Bernhardt, PhD, The Florey Institute of Neuroscience and Mental Health
  • Principal Investigator: Leonid Churilov, PhD, The Florey Institute of Neuroscience and Mental Health
  • Principal Investigator: Helen Dewey, MD, Monash University
  • Principal Investigator: Richard Lindley Dewey, MD, George Institute for Global Health
  • Principal Investigator: Janice Collier, PhD, The Florey Institute of Neuroscience and Mental Health
  • Principal Investigator: Amanda Thrift, PhD, Monash University
  • Principal Investigator: Geoffrey Donnan, MD, The Florey Institute of Neuroscience and Mental Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2006

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

January 1, 2015

Study Registration Dates

First Submitted

April 30, 2013

First Submitted That Met QC Criteria

May 2, 2013

First Posted (Estimate)

May 3, 2013

Study Record Updates

Last Update Posted (Estimate)

April 15, 2015

Last Update Submitted That Met QC Criteria

April 13, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • version3 25April08
  • ACTRN12606000185561 (Registry Identifier: ANZCTR)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Standard care

3
Subscribe